1887

Chapter 11.19 : Gamma Interferon Enzyme-Linked Immunospot Assay

MyBook is a cheap paperback edition of the original book and will be sold at uniform, low price.

Preview this chapter:
Zoom in
Zoomout

Gamma Interferon Enzyme-Linked Immunospot Assay, Page 1 of 2

| /docserver/preview/fulltext/10.1128/9781555817435/9781555815271_Chap11_19-1.gif /docserver/preview/fulltext/10.1128/9781555817435/9781555815271_Chap11_19-2.gif

Abstract:

The enzyme-linked immunospot (ELISPOT) assay was described more than 13 years ago for the detection of specific immune cells at the single-cell level. The utility of the gamma interferon (IFN-γ) ELISPOT assay in detecting antigen-specific T cells was initially demonstrated in models of autoimmune and infectious diseases. Optimization of the assay through the introduction of specifically designed antibodies, 96-well plates, substrate kits, and other modifications has broadened the potential uses for the IFN-γ ELISPOT assay. Today, it is being used for a wide range of applications, including monitoring responses in patients with cancer undergoing immunotherapeutic treatment and monitoring specific immune response patterns in patients with infectious, neoplastic, or autoimmune diseases. Additionally, it has been an important tool in the identification of immunodominant epitopes in human immunodeficiency virus and infections, as well as in the development of specific vaccine strategies ( ).

Citation: Garcia L. 2010. Gamma Interferon Enzyme-Linked Immunospot Assay, p 258-263. In Clinical Microbiology Procedures Handbook, 3rd Edition. ASM Press, Washington, DC. doi: 10.1128/9781555817435.ch11.19
Highlighted Text: Show | Hide
Loading full text...

Full text loading...

References

/content/book/10.1128/9781555817435.chap11.19
1. Dubey, S.,, J. Clair,, T. M. Fu,, L. Guan,, R. Long,, R. Mogg,, K. Anderson,, K. B. Collins,, C. Gaunt,, V. R. Fernandez,, L. Zhu,, L. Kierstead,, S. Thaler,, S. B. Gupta,, W. Straus,, D. Mehrotra,, T. W. Tobery,, D. R. Casimiro,, and J. W. Shiver. 2007. Detection of HIV vaccine-induced cell-mediated immunity in HIV-seronegative clinical trial participants using optimized and validated enzyme-linked immunospot assay. J. Acquir. Immune Defic. Syndr. 45:2027.
2. Janetzki, S.,, J. H. Cox,, N. Oden,, and G. Ferrari,. 2005. Standardization and validation issues of the ELISPOT assay, p. 5186. In A. E. Kalyuzhny (ed.), Manual of ELISPOT. Humana Press, Totowa, NJ.

This is a required field
Please enter a valid email address
Please check the format of the address you have entered.
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error